Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Holy Cross Hospital
Fort Lauderdale, Florida, United States
- Lakeland Regional Health Care/cancer Center
Lakeland, Florida, United States
- University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, United States
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
- St. Vincent Frontier Cancer Center
Billings, Montana, United States
- the West Clinic, Pc
Memphis, Tennessee, United States
- Us Oncology / Texas Oncology, P.A.
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2015
- Primary completion
- 22 Sept 2017
- Completion
- 22 Sept 2017
- Last update posted
- 18 Nov 2020
- Registered enrollment
- 32
- Registry id
- NCT02368691
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.